Laverock Therapeutics Launches In Vivo Programmes in Oncology and Genetic Medicine
Laverock Therapeutics has added in vivo programmes to its pipeline, extending its programmable gene control platform beyond ex vivo cell therapies. The programmes target in vivo CAR-T for solid tumours and in vivo gene silencing in genetic medicine, with an initial focus on nervous system disorders and metabolic disease.